OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:411696
Who is this for?
Show terms as
View depth
8Treatment centers

Where are you in your journey?

UniteRare data is compiled from authoritative primary sources (FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, NORD), then processed through automated and AI-assisted extraction pipelines.
Report missing data

What is OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia?

Proton-pump inhibitor-responsive esophageal eosinophilia (PPI-REE) is an obsolete diagnostic term that was previously used to describe a condition where the esophagus (the tube connecting the mouth to the stomach) becomes inflamed with a type of white blood cell called eosinophils, and this inflammation improves when treated with proton-pump inhibitor (PPI) medications such as omeprazole or lansoprazole. Patients with this condition experience symptoms very similar to eosinophilic esophagitis (EoE), including difficulty swallowing, food getting stuck in the throat, chest pain, and heartburn. This diagnosis is now considered obsolete because medical experts have recognized that PPI-REE is not a separate disease from eosinophilic esophagitis. Updated guidelines from gastroenterology societies now consider PPI-responsive cases to be part of the eosinophilic esophagitis spectrum. In other words, responding to PPI therapy does not rule out a diagnosis of EoE — it simply means that PPIs are an effective treatment option for that patient's EoE. This reclassification happened because research showed that the clinical features, genetic profiles, and tissue characteristics of PPI-REE and classic EoE are essentially the same. Patients who were previously diagnosed with PPI-REE should now be managed under the broader diagnosis of eosinophilic esophagitis. Treatment includes dietary elimination strategies, swallowed topical corticosteroids (such as budesonide or fluticasone), and PPI therapy, which is now recognized as a legitimate first-line treatment for EoE rather than just a diagnostic tool.

Key symptoms:

Difficulty swallowing solid foodsFood getting stuck in the throat or chestHeartburn or chest painUpper abdominal painNauseaVomitingRegurgitation of foodFeeling like something is stuck in the throatAvoidance of certain food texturesSlow eating or excessive chewingWeight loss or poor weight gain in childrenFeeding difficulties in young children

Inheritance
Multifactorial
Caused by a mix of several genes and environmental factors
Age of Onset
Variable
Can begin at different ages, from infancy through adulthood
Orphanet ↗NORD ↗

Treatments

Source: openFDA + DailyMed · NDA / BLA labels with structured indications · refreshed weekly

No FDA-approved treatments are currently listed for OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia.

View clinical trials →

Source: ClinicalTrials.gov · synced daily · phases, status, and PI names normalized at ingest

No actively recruiting trials found for OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia community →

Source: NPI Registry + PubMed · trial PI roles cross-referenced with ClinicalTrials.gov · ranked by match score (publications + PI activity + community signal)

No specialists are currently listed for OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers

Source: NORD Rare Disease Centers + NIH Undiagnosed Diseases Network (UDN) · centers verified active within last 12 months

🏨 Children's

Children's Hospital Colorado Rare Disease Program

Children's Hospital Colorado

📍 Aurora, CO

👤 Boston Children's Hospital Rare Disease Program

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Boston Children's Hospital Rare Disease Program

Boston Children's Hospital

📍 Boston, MA

👤 Boston Children's Hospital Rare Disease Program

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

🏨 Children's

Ann & Robert H. Lurie Children's Hospital Genetics

Lurie Children's Hospital

📍 Chicago, IL

👤 Boston Children's Hospital Rare Disease Program

🏥 NORD

Cincinnati Children's Hospital Medical Center

Cincinnati Children's

📍 Cincinnati, OH

👤 Boston Children's Hospital Rare Disease Program

🏨 Children's

Nationwide Children's Hospital Rare Disease Center

Nationwide Children's Hospital

📍 Columbus, OH

👤 Boston Children's Hospital Rare Disease Program

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

Travel Grants

No travel grants are currently matched to OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia.

Search all travel grants →NORD Financial Assistance ↗

Community

Open OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophiliaForum →

No community posts yet. Be the first to share your experience with OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia.

Start the conversation →

Latest news about OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia

Source: PubMed + NIH RePORTER + openFDA + clinical-journal RSS · last 30 days · disease-tagged at ingest by AI extraction with human QC

No recent news articles for OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.Since PPI-REE is now considered part of eosinophilic esophagitis, does my diagnosis or treatment plan need to change?,Which treatment approach do you recommend first — PPI therapy, dietary elimination, or swallowed steroids?,How often will I need repeat endoscopies to check if treatment is working?,Should I see an allergist to identify specific food triggers?,Am I a candidate for dupilumab (Dupixent) if other treatments don't work well enough?,What should I do if food gets stuck in my esophagus and I can't swallow?,Is this a condition I will need to manage for the rest of my life?

Common questions about OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia

What is OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia?

Proton-pump inhibitor-responsive esophageal eosinophilia (PPI-REE) is an obsolete diagnostic term that was previously used to describe a condition where the esophagus (the tube connecting the mouth to the stomach) becomes inflamed with a type of white blood cell called eosinophils, and this inflammation improves when treated with proton-pump inhibitor (PPI) medications such as omeprazole or lansoprazole. Patients with this condition experience symptoms very similar to eosinophilic esophagitis (EoE), including difficulty swallowing, food getting stuck in the throat, chest pain, and heartburn.

How is OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia inherited?

OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia follows a multifactorial inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

Frequently asked questions about OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia

Auto-generated from canonical disease facts (Orphanet, OMIM, ClinicalTrials.gov, openFDA, NPPES). Not a substitute for clinical guidance.

  1. What is OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia?

    OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia is a rare disease catalogued in international rare-disease ontologies (Orphanet ORPHA:411696). It is typically inherited as multifactorial. Age of onset is generally variable. For verified primary sources, see the UniteRare OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia page.

  2. How is OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia inherited?

    OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia follows multifactorial inheritance. Genetic counseling is recommended for affected families to understand recurrence risk in offspring and the likelihood of unaffected siblings being carriers. Variants in the underlying gene(s) may be identified via clinical genetic testing.

  3. Are there FDA-approved treatments for OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia?

    Approved treatments for OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia are tracked from openFDA and DailyMed primary sources. Many rare diseases have no specific FDA-approved therapy; for those, supportive care and management of complications form the basis of clinical care. Orphan-drug-designation status is noted where applicable.

  4. Are there clinical trials for OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia?

    Active clinical trials for OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia are tracked daily from ClinicalTrials.gov. Trial availability changes frequently; check the UniteRare trial listings for the current count and recruitment status. Sponsors of rare-disease research often welcome inquiries even when a trial is not actively recruiting at a given moment.

  5. How do I find a specialist for OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia?

    Verified OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia specialists are identified through ClinicalTrials.gov principal-investigator records, peer-reviewed publication authorship (via PubMed), and the NPPES NPI registry. NORD-designated Centers of Excellence and NIH-affiliated rare-disease clinics are also tracked. UniteRare's specialist directory is updated continuously as new evidence becomes available.

See full OBSOLETE: Proton-pump inhibitor-responsive esophageal eosinophilia page for complete clinical details, sources, and verified-specialist listings.

Cite this page

Select a citation format above to view and copy.